Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | ANPEP | P15144 | 1/20 | 0.30 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.30 |
| ▸ | LAP3 | P28838 | 1/20 | 0.30 |
| ▸ | TYMS | P04818 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxidronic Acid SCHEMBL393281 | 0.89 | KDM4E (0.40) | KDM4EMMP2THRBMAPK1HSD17B10 | |
| Oxidronic Acid SCHEMBL8958458 | 0.85 | KDM4E (0.38) | KDM4EMMP2THRBMAPK1HSD17B10 | |
| Oxidronic Acid SCHEMBL29363818 | 0.85 | KDM4E (0.38) | KDM4EMMP2THRBMAPK1HSD17B10 | |
| Oxidronic Acid SCHEMBL28460122 | 0.85 | KDM4E (0.38) | KDM4EMMP2THRBMAPK1HSD17B10 | |
| Oxidronic Acid SCHEMBL1478075 | 0.85 | KDM4E (0.38) | KDM4EMMP2THRBMAPK1HSD17B10 | |
| Phosphoric Acid SCHEMBL29694 | 0.71 | CA2 (0.42) | KDM4EMMP2THRBMAPK1HSD17B10 | |
| Phosphoric Acid SCHEMBL6324254 | 0.71 | CA2 (0.42) | KDM4EMMP2THRBMAPK1HSD17B10 | |
| Phosphoric Acid SCHEMBL1500439 | 0.71 | CA2 (0.42) | KDM4EMMP2THRBMAPK1HSD17B10 | |
| Phosphoric Acid SCHEMBL8672238 | 0.71 | CA2 (0.42) | KDM4EMMP2THRBMAPK1HSD17B10 | |
| Phosphoric Acid SCHEMBL15270536 | 0.71 | CA2 (0.42) | KDM4EMMP2THRBMAPK1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1981837-A2 | METHODS AND COMPOSITIONS FOR MODULATING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ACTIVITY | Praecis Pharmaceuticals Incorporated (US) | 2008-10-22 | — | — | EP | disclosed |
| US-20080064662-A1 | Methods and compositions for modulating sphingosine -1- phosphate (S1P) receptor activity | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2008-03-13 | — | — | US | disclosed |
| WO-2007092190-A2 | METHODS AND COMPOSITIONS FOR MODULATING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ACTIVITY | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-08-16 | — | — | WO | disclosed |
| US-7241812-B2 | Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-07-10 | — | — | US | disclosed |
| EP-1781595-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ACTIVITY | Praecis Pharmaceuticals Inc. (US) | 2007-05-09 | — | — | EP | disclosed |
| US-20060223866-A1 | Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity | PRAECIS PHARMACEUTICALS, INC. (US) | 2006-10-05 | — | — | US | disclosed |
| US-20060135786-A1 | Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity | PRAECIS PHAMACEUTICALS, INC. (US) | 2006-06-22 | — | — | US | disclosed |
| WO-2006020951-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ACTIVITY | PRAECIS PHARMACEUTICALS, INC. (US) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064662-A1 | Methods and compositions for modulating sphingosine -1- phosphate (S1P) receptor activity | S1PR1, S1PR2, S1PR3 | KDM4E 3325/4885MMP2 2718/4885THRB 514/4885 |
| US-20060223866-A1 | Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity | S1PR1, S1PR2, S1PR3 | KDM4E 3325/4885MMP2 2718/4885THRB 514/4885 |
| US-20060135786-A1 | Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity | S1PR1, S1PR2, S1PR3 | KDM4E 3325/4885MMP2 2718/4885THRB 514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.